Why is the US targeting Germany's drug industry?
dwSaturday, June 27, 2026
A new trade probe is reigniting a long-running clash over who should pay for medical innovation. Washington argues Germans benefit from lower prices while US patients shoulder a disproportionate share of the costs.
Primary Scripture
Community launching soon
Get the invite by email when the Watchman's Wall opens
Share this article
Source: dw— we link to the original for full context.